RÉSUMÉ
Recurrent idiopathic neuroretinitis is an inflammatory optic neuropathy characterized by optic nerve edema and macular star, associated with painless and recurrent episodes of visual loss, poor visual prognosis, and visual field defects related to nerve fiber layer injury. The disorder is sometimes mistaken for atypical optic neuritis. However, early diagnosis is important for visual recovery. Long-term immunosuppression has been shown to reduce the rate of recurrence and protect against severe and irreversible vision loss.
Sujet(s)
Névrite optique/diagnostic , Rétinite/diagnostic , Adulte , Diagnostic différentiel , Exsudats et transsudats , Humains , Macula/métabolisme , Macula/anatomopathologie , Mâle , Névrite optique/anatomopathologie , Récidive , Rétinite/complications , Rétinite/anatomopathologie , Tomographie par cohérence optique , Troubles de la vision/étiologie , Acuité visuelle , Tests du champ visuelRÉSUMÉ
ABSTRACT Recurrent idiopathic neuroretinitis is an inflammatory optic neuropathy characterized by optic nerve edema and macular star, associated with painless and recurrent episodes of visual loss, poor visual prognosis, and visual field defects related to nerve fiber layer injury. The disorder is sometimes mistaken for atypical optic neuritis. However, early diagnosis is important for visual recovery. Long-term immunosuppression has been shown to reduce the rate of recurrence and protect against severe and irreversible vision loss.
RESUMO Neurorretinite recorrente idiopática é uma neuropatia óptica inflamatória caracterizada por edema do nervo óptico e estrela macular associada a episódios recorrentes de perda visual indolor, baixo prognóstico visual e desfeitos de campo visual relacionados a injúria da camada de fibras nervosas. Essa condição pode ser confundida com neurite óptica atípica e seu correto diagnóstico é importante para o prognóstico visual, uma vez que a imunossupressão continua previne episódios recorrentes que podem levar a perda visual severa e irreversível.
Sujet(s)
Humains , Mâle , Adulte , Rétinite/diagnostic , Névrite optique/diagnostic , Récidive , Rétinite/complications , Rétinite/anatomopathologie , Troubles de la vision/étiologie , Acuité visuelle , Névrite optique/anatomopathologie , Tomographie par cohérence optique , Diagnostic différentiel , Exsudats et transsudats , Tests du champ visuel , Macula/métabolisme , Macula/anatomopathologieRÉSUMÉ
OBJECTIVES: To examine the associations of macular pigment carotenoids (lutein, meso-zeaxanthin, and zeaxanthin), aerobic fitness, and central adiposity with hippocampal-dependent relational memory in prepubescent children. STUDY DESIGN: Children between 7 and 10 years of age (n = 40) completed a task designed to assess relational memory performance and participated in aerobic fitness, adiposity, and macular pigment optical density (MPOD) assessment. Aerobic fitness was assessed via a modified Balke treadmill protocol designed to measure maximal oxygen volume. Central adiposity was assessed via dual-energy x-ray absorptiometry. MPOD was measured psychophysically by the use of customized heterochromatic flicker photometry. Statistical analyses included correlations and hierarchical linear regression. RESULTS: Aerobic fitness and MPOD were associated negatively with relational memory errors (P < .01), whereas central adiposity was associated positively with relational memory errors (P < .05). Hierarchical regression analysis revealed that MPOD accounted for a significant amount of the variance in relational memory performance even after we accounted for aerobic fitness (ß = -0.388, P = .007). CONCLUSIONS: Even after we adjusted for aerobic fitness and central adiposity, factors known to relate to hippocampal-dependent memory, MPOD positively and significantly predicted hippocampal-dependent memory performance. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01619826.
Sujet(s)
Caroténoïdes/métabolisme , Hippocampe/métabolisme , Macula/métabolisme , Troubles de la mémoire/diagnostic , Obésité abdominale/diagnostic , Aptitude physique/physiologie , Facteurs âges , Marqueurs biologiques/métabolisme , Enfant , Études de cohortes , Femelle , Hippocampe/physiologie , Humains , Lutéine/métabolisme , Mâle , Mémoire/physiologie , Troubles de la mémoire/métabolisme , Photométrie , Études prospectives , Analyse de régression , Sensibilité et spécificité , Zéaxanthines/métabolismeRÉSUMÉ
PURPOSE: Retinal photocoagulation and nondamaging laser therapy are used for treatment of macular disorders, without understanding of the response mechanism and with no rationale for dosimetry. To establish a proper titration algorithm, we measured the range of tissue response and damage threshold. We then evaluated safety and efficacy of nondamaging retinal therapy (NRT) based on this algorithm for chronic central serous chorioretinopathy (CSCR) and macular telangiectasia (MacTel). METHODS: Retinal response to laser treatment below damage threshold was assessed in pigmented rabbits by expression of the heat shock protein HSP70 and glial fibrillary acidic protein (GFAP). Energy was adjusted relative to visible titration using the Endpoint Management (EpM) algorithm. In clinical studies, 21 eyes with CSCR and 10 eyes with MacTel were treated at 30% EpM energy with high spot density (0.25-diameter spacing). Visual acuity, retinal and choroidal thickness, and subretinal fluid were monitored for 1 year. RESULTS: At 25% EpM energy and higher, HSP70 was expressed acutely in RPE, and GFAP upregulation in Müller cells was observed at 1 month. Damage appeared starting at 40% setting. Subretinal fluid resolved completely in 81% and partially in 19% of the CSCR patients, and visual acuity improved by 12 ± 3 letters. Lacunae in the majority of MacTel patients decreased while preserving the retinal thickness, and vision improved by 10 letters. CONCLUSIONS: Heat shock protein expression in response to hyperthermia helps define the therapeutic window for NRT. Lack of tissue damage enables high-density treatment to boost clinical efficacy, therapy in the fovea, and retreatments to manage chronic diseases.